Introduction
Paraneoplastic syndromes are malignancy symptoms, which are directly linked to the p r i m a r y t u m o r o r i t s m e t a s t a s e s . ( 1 ) Approximately 8-10% of cancer patients suffer from a paraneoplastic syndrome . In (1) some cases, the paraneoplastic syndrome precedes the neoplasia.
Their recognition is therefore important as it can lead to the early diagnosis of a neoplasia in a stage with high chances of treatment success. Inflammatory rheumatic diseases sometimes represent the first manifestations of a neoplasia. Among the most frequent we mention dermatomyositis, hypertrophic osteoarthropathy or leukocytoclastic vasculitis . Although the association between (1) systemic scleroderma (SSc) and neoplasia is well known, it is however not regarded as high risk . 
Clinical examination
On admission, the patient was afebrile, had a facies which suggested a "byzantine icon" -type, with mild microstomia, long, thin nose and perioral wrinkles, sclerodactilia, diffuse following childhood trauma; she was also cardio-pulmonary stable, with no other s i g n i f i c a n t e l e m e n t s a t t h e c l i n i c a l examination.
Investigations
Usual laboratory tests, including complete blood count(CBC) and biochemistry panel Concerning the association of systemic scleroderma with paraneoplastic disorders, it can coexist with a cancer , but this ( 4 ) association is probably underestimated due to the high mortality rate given by systemic A l s o , i t s e e m s t h a t p o s i t i v e a n t itopoisomerase I antibodies are associated with the presence of paraneoplastic syndromes . Among all these criteria, our (4) p a t i e n t e n c o m p a s s e s a t l e a s t f o u r enumerated features, which makes the suspicion of systemic scleroderma as paraneoplastic syndrome to be well justified in this case.
The antinuclear antibodies (ANA) that are most often encountered in rheumatic diseases represent a lower frequency in the malignant disorders, but still with an important percentage of about 10-20% . (8, 9) There are studies that have evaluated the prevalence of ANA in patients with malignant diseases and the possibility that their presence could be involved in the onset of p a r a n e o p l a s t i c s y n d r o m e s a n d t h e development od musculoskeletal symptoms.
It seems there is a high incidence of ANA in malignant disorders and in the case of neoplastic patients with positive ANA, the frequency of paraneoplastic syndromes and musculoskeletal symptoms is much more higher compared to neoplastic patients with negative ANA or with healthy subjects . A (10) study conducted in 2018 has confirmed these results , ANA having a frequency of almost 40% among the patients with paraneoplastic syndromes included in the study . 
